Brief: Phasebio Launches Clinical Trial To Evaluate Pb1046 As A Treatment For Hospitalized Covid-19 Patients

PhaseBio Pharmaceuticals

27/05/2020 21:12

May 27 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO LAUNCHES CLINICAL TRIAL TO EVALUATE PB1046 AS A
TREATMENT FOR HOSPITALIZED COVID-19 PATIENTS
    * PHASEBIO PHARMA - RECEIVES CLEARANCE OF IND APPLICATION
FROM
U.S. FDA UNDER CORONAVIRUS TREATMENT ACCELERATION PROGRAM
    * PHASEBIO PHARMACEUTICALS - TARGETING TO REPORT VANGARD
TRIAL
RESULTS LATE IN Q4 OF 2020
    * PHASEBIO PHARMACEUTICALS -  EXPECTS TO BEGIN DOSING
PATIENTS BY
END OF JUNE IN VANGARD TRIAL

Source text for Eikon:  ID:nBw1Ych6La 
Further company coverage:  PHAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))